The diffuse-type tenosynovial giant cell tumor (dt-TGCT) patient journey: a prospective real-world study

Nicholas M. Bernthal(Harvard University), Michiel A. J. van de Sande(Leiden University Medical Center), John H. Healey(Memorial Sloan Kettering Cancer Center), Hans Gelderblom(Leiden University Medical Center), Sebastian Bauer(Science for Life Laboratory), Julio López‐Bastida(Daiichi Sankyo (Germany)), Silvia Stacchiotti(Fondazione IRCCS Istituto Nazionale dei Tumori), Emanuela Palmerini(Istituto Ortopedico Rizzoli), Xin Ye(University of Georgia), Geert Spierenburg(Leiden University Medical Center), TOPP Study Group(Leiden University Medical Center), Petra Laeis(Daiichi Sankyo (Germany)), Eva‐Maria Fronk(Daiichi Sankyo (Germany)), Eric L. Staals(Istituto Ortopedico Rizzoli)
Research Square (Research Square)
April 15, 2020
10.21203/rs.3.rs-22089/v1
Cited by 0

Related Papers

Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
|The Lancet|2012|2.1k
Cremophor EL
|European Journal of Cancer|2001|1.6k
Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2018|1.6k
Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial
|The Lancet|2012|1.4k
Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial
|The Lancet Oncology|2014|1.2k